Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD.
Chief Executive Of
Mesoblast (NASDAQ:MESO) released full-year financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Friday after the company announced that Ryoncil received a J-Code from the United States Medicare & Medicaid Services, streamlining billing and payment processes for the product.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.
